Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Payables (2019 - 2025)

Historic Payables for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to $27.2 million.

  • Strata Critical Medical's Payables rose 6982.78% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 6982.78%. This contributed to the annual value of $9.2 million for FY2024, which is 6135.63% down from last year.
  • According to the latest figures from Q3 2025, Strata Critical Medical's Payables is $27.2 million, which was up 6982.78% from $13.7 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Payables ranged from a high of $27.2 million in Q3 2025 and a low of $1.3 million during Q1 2021
  • For the 5-year period, Strata Critical Medical's Payables averaged around $12.4 million, with its median value being $11.4 million (2023).
  • In the last 5 years, Strata Critical Medical's Payables skyrocketed by 485800.0% in 2021 and then plummeted by 6135.63% in 2024.
  • Quarter analysis of 5 years shows Strata Critical Medical's Payables stood at $6.4 million in 2021, then surged by 159.63% to $16.5 million in 2022, then skyrocketed by 44.29% to $23.9 million in 2023, then plummeted by 61.36% to $9.2 million in 2024, then soared by 195.23% to $27.2 million in 2025.
  • Its Payables was $27.2 million in Q3 2025, compared to $13.7 million in Q2 2025 and $10.5 million in Q1 2025.